Research Papers:
LDB2 inhibits proliferation and migration in liver cancer cells by abrogating HEY1 expression
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1381 views | HTML 2248 views | ?
Abstract
Hongyang Yu1, Ruichun Jia2, Ling Zhao3, Shigang Song1, Jing Gu4 and Haogang Zhang5
1Department of Radiation Oncology, The Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China
2Department of Blood Transfusion, The Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China
3Oncology Department of Internal Medicine, The Third Affiliated Hospital of Harbin Medical University, Harbin 150040, China
4Department of Anesthesia, The Third Affiliated Hospital of Harbin Medical University, Harbin 150040, China
5Department of General Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China
Correspondence to:
Haogang Zhang, email: [email protected]
Keywords: HCC, LDB2, BRD7, proliferation, HEY1
Received: July 20, 2017 Accepted: September 20, 2017 Published: October 10, 2017
ABSTRACT
Hepatocellular carcinoma (HCC) was one of the most common cancers around the world, has very low 5-year survival rate. However, the mechanism of HCC occurrence and development is largely unknown. LDB2 belongs to the LIM-domain binding family and functions as an adaptor for transcriptional regulation. Here we found that LDB2 is downregulated in HCC samples. LDB2 has the ability to inhibit proliferation and migration of hepatocarcinoma cells. We found that the proliferation and migration abilities in HCC sample cells were impaired after LDB2 overexpression and vice versa. In mechanism, we found that LDB2 can recruit BRD7 to HEY1 promoter and then block its expression. HEY1 whose expression is upregulated in HCC acts as an oncogene. In brief, our research reveals a new regulatory mechanism for hepatocarcinoma cell proliferation and migration.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21772